Journal of Clinical Oncology
Articles in this Issue
Body mass index–stratified outcomes with first-line immunotherapy in metastatic RCC: A real-world analysis.
e16507 Background: Obesity is a known risk factor for renal cell carcinoma (RCC) yet paradoxically has been linked to bett...
Outcomes and factors associated with first line chemoimmunotherapy (ChemoIO) or immunotherapy (IO) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
e18095 Background: IO alone or with chemotherapy, is standard first-line therapy for recurrent/metastatic HNSCC. This stud...
Pre-progression discontinuation and off-treatment progression-free interval after enfortumab vedotin–based therapy among patients with clinical benefit in advanced urothelial carcinoma: A single-institution experience.
e16593 Background: In routine practice, enfortumab vedotin (EV) ± pembrolizumab (EVP) may be discontinued before progressi...
A phase II study of amivantamab hyaluronidase in <i>MET</i> amplification–positive stage IV or recurrent non–small cell lung cancer (Lung-MAP Sub-Study).
TPS8680 Background: MET amplification is a known oncogenic driver in non-small cell lung cancer (NSCLC...
Breast cancer survivorship program: Assessing and addressing patients’ needs.
e13795 Background: Breast cancer (BC) survivors face diverse physical and psychological challenges, often due to treatment...
Baseline skeletal muscle index as an independent prognostic factor in locally advanced head and neck squamous cell carcinoma: A post hoc analysis of the REACH trial.
6088 Background: The prognosis for locally advanced squamous cell carcinoma of the head and neck (LAHNSCC) is heterogeneou...
Utilization of a psychosocial oncology consult service pre-post a one-session educational intervention.
e24115 Background: Psychosocial oncology consultation services (POCS) address the psychosocial needs of hospitalized patie...
Association between low muscle mass assessed by bioelectrical impedance analysis and clinical outcomes in hospitalized cancer patients.
11034 Background: Low muscle mass is an independent prognostic marker associated with increased clinical risk, functional...
Trends in non-epithelial ovarian malignancies in patients younger than 51 from 2004 to 2022 in the United States.
e17554 Background: Non-epithelial ovarian cancers (NOCs) are rare but disproportionately affect younger patients (pts), wh...
Trends and disparities in lung cancer and renal failure–related mortality in the United States, 1999-2023.
e23372 Background: Lung cancer is the leading cause of oncological mortality in the U.S, a burden frequently increased by...
Early intravenous immunoglobulin use in multiple myeloma patients treated with talquetamab: Effect on risk of infections and mortality.
7573 Background: Bispecific T-cell–engaging (BiTE) antibodies have transformed the treatment of relapsed or refractory mul...
Identification of checkpoint inhibitor resistance mechanisms in leiomyosarcoma through enrichment of active chromatin-associated cell-free DNA.
11545 Background: Leiomyosarcoma (LMS) is a sarcoma subtype with poor metastatic outcomes and limited treatment options. C...
Technical performance of online adaptive radiotherapy in managing inter-fractional anatomical deformation during moderately hypofractionated prostate cancer treatment.
e23158 Background: Inter-fractional variability of pelvic organ anatomy introduces non-linear geometric uncertainty that c...
Real-world overall survival with platinum–pemetrexed chemotherapy versus ipilimumab–nivolumab in peritoneal mesothelioma: A propensity-matched multicenter analysis.
e23442 Background: Peritoneal mesothelioma is a rare malignancy with limited data guiding optimal first-line systemic ther...
Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
11006 Background: Despite antiemetic guidelines, ~50% of patients (pts) receiving moderately emetogenic chemotherapy (MEC)...
Germline <i>RET</i> variants in medullary thyroid carcinoma: A single-center experience from 2019 to 2025.
e18051 Background: Medullary thyroid carcinoma (MTC) accounts for approximately 1–2% of all thyroid cancers and is heredit...
EMITT-1: Clinical and pharmacodynamic activity with the oral ERAP1 inhibitor GRWD5769 and cemiplimab in 6 completed phase 1b expansion cohorts in solid tumors with anti–PD-1 resistance or MSS-CRC.
2500 Background: Resistance to anti-PD-1 therapy remains a major unmet need. GRWD5769 is a first-in-class oral End...
Outcomes of systemic therapy followed by surgery for synchronous liver metastases from pancreatic cancer: A multicenter retrospective cohort study.
e16365 Background: The role of surgical intervention in pancreatic ductal adenocarcinoma with synchronous liver metastases...
Distribution of BRAF functional classes across select tumor lineages with implications in current targeted therapy paradigms.
e15176 Background: BRAF -driven oncogenesis is biologically heterogeneous, and the clinical relevance...
Transcriptomic profiling to identify cancer–immune meta-programs in penile squamous cell carcinoma.
e17035 Background: Penile squamous cell carcinoma (PSCC) is a rare malignancy with substantial heterogeneity in tumor-intr...
Behavioral predictors of pain control among adult cancer survivors: Examining the impact of smoking, physical activity, and alcohol consumption.
12048 Background: Cancer-related pain remains a prevalent and debilitating symptom among adult cancer survivors, substanti...
ASP2998, a trophoblast cell-surface antigen 2 (TROP2)–targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study.
TPS2665 Background: TROP2 is a type I transmembrane glycoprotein involved in cell proliferation, migration, and survival,...
Organ-specific progression and AI-based prognostic modeling in metastatic NSCLC treated with chemo-immunotherapy.
e20585 Background: Organ-specific progression patterns and survival outcomes in metastatic non–small cell lung cancer (NSC...
Predictive factors of biochemical recurrence after robot-assisted radical prostatectomy: Results from a monocentric cohort.
e17128 Background: Robot-assisted radical prostatectomy is a modern surgical approach for the treatment of localized prost...
Association of progression-free survival (PFS) with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) status determined by single vs dual validated companion diagnostic (CDx) assays: CheckMate-8HW post hoc analyses.
3531 Background: First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) showed PFS benefit vs chemotherapy (chemo) in patient...